Fresenius Medical Care (FMEG.DE): Expect Q2 26 to demonstrate another solid quarter of EBIT growth but US SMTG to remain subdued; Neutral
Report Coverage
- Broker
- Goldman Sachs
- Region
- Greater China, United States
- Report Type
- Market Report
- Primary Focus
- Expect Q2 26 to demonstrate another solid quarter of EBIT growth but US SMTG to FMEG.
Full Report Document Access
This page is a research report summary and access guidance page. If you are searching for Goldman Sachs Fresenius Medical Care (FMEG.DE) research report PDF or the full report document, use the summary, coverage fields and related links to confirm relevance before requesting VIP access. Full PDF report access is available to VIP members after request confirmation; the PDF is not publicly displayed on this page.
Report Summary
Expect Q2 26 to demonstrate another solid quarter of EBIT growth but US SMTG to FMEG.DE 12m Price Target: €43.00 Price: €40.70 Upside: 5.7% NEUTRAL We are updating our estimates for Fresenius Medical Care prior +44(20)7552-7872 | [email protected] to Q2 26 results. At the group level we expect another solid quarter
Key Takeaways
- 0.3%. Despite our expectations for subdued SMTG, we do expect another quarter of
- Expect Q2 26 to demonstrate another solid quarter of EBIT growth but US SMTG to FMEG.
- DE 12m Price Target: €43.
- 7% NEUTRAL We are updating our estimates for Fresenius Medical Care prior +44(20)7552-7872 | richard.
Why This Report Matters
Goldman Sachs's 10-page analysis on "Fresenius Medical Care (FMEG.DE): Expect Q2 26 to demonstrate another solid quarter of EBIT growth b" provides institutional-grade insights for investors and professionals seeking to understand current market dynamics and investment implications in this space.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the Goldman Sachs Fresenius Medical Care (FMEG.DE) report. It helps users review Fresenius Medical Care (FMEG.DE): Expect Q2 26 to demonstrate another solid quarter of EBIT growth but US SMTG to remain subdued; Neutral coverage, key takeaways, and related broker or sector research paths across EV, revenue, M&A; Equity Research, June.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.